The Washington Post on MSN9d
FDA approves a novel drug for schizophrenia, a potential ‘game changer’
The U.S. Food and Drug Administration ... the agency approved Cobenfy without a “black box” warning on the regulatory label ...
studyfinds9d
Alzheimer’s drug breakthrough or breakdown? Investigation exposes red flags in FDA approval of donanemab
A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...
Critical Flaws: New Alzheimer’s Drug Could Actually Be a Safety Risk
An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...
FDA approves new schizophrenia drug
The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.
Alzheimer’s Breakthrough: Synthetic THC Pill Proves Effective in Clinical Trial
Patients tolerated synthetic THC (dronabinol) well, without the adverse effects commonly associated with existing Alzheimer's ...
朝日新聞社3d
US approves Alzheimer’s drug that modestly slows disease
Last week, a congressional report found that FDA's approval of a similar Alzheimer's drug called Aduhelm — also from Biogen and Eisai — was “rife with irregularities,” including a number ...
ABC News9d
FDA approves 1st new drug for schizophrenia in more than 30 years
The medication, Cobenfy, combines two drugs and is taken as a twice-daily pill. The U.S. Food and Drug Administration (FDA) on Thursday ... including the treatment of Alzheimer's disease and ...
Newsweek8d
FDA Approves New Schizophrenia Drug in 70-Year First
The U.S. Food and Drug Administration has approved a new drug for schizophrenia ... for a range of neurological diseases, including Alzheimer's disease, Parkinson's and schizophrenia.
US FDA approves IntraBio's drug for rare genetic disease
Niemann-Pick disease type C (NPC) is a rare genetic disorder that affects the nervous system and other organs, causing ...
i10d
Alzheimer’s ‘wonder drug’ was recommended by scientists funded by pharma firms
A BMJ investigation found seven of the eight doctors appointed by the US Food & Drug Administration (FDA) to review donanemab ...
BMJ10d
Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer’s drug
A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the “independent” advisory ...
i10d
Alzheimer’s ‘wonder drug’ was approved by scientists funded by pharma firm
A BMJ investigation found seven of the eight doctors appointed by the US Food & Drug Administration (FDA) to review donanemab ...